title: Tolerance of high-dose (3,000 mg/day) coenzyme Q10 in ALS.
abstract: An open-label dose-escalation trial was performed to assess the safety and tolerability of high doses of coenzyme Q10 (CoQ10) in ALS. CoQ10, a cofactor in mitochondrial electron transfer, may improve the mitochondrial dysfunction in ALS. In this study, CoQ10 was safe and well tolerated in 31 subjects treated with doses as high as 3,000 mg/day for 8 months.
authors.affiliation: Neurology Clinical Trials Unit, Massachusetts General Hospital, Harvard Medical School, Boston, MA, USA. kimberly.ferrante@umassmed.edu
authors.forename: K L
authors.initials: KL
authors.lastname: Ferrante
authors.forename: J
authors.initials: J
authors.lastname: Shefner
authors.forename: H
authors.initials: H
authors.lastname: Zhang
authors.forename: R
authors.initials: R
authors.lastname: Betensky
authors.forename: M
authors.initials: M
authors.lastname: O'Brien
authors.forename: H
authors.initials: H
authors.lastname: Yu
authors.forename: M
authors.initials: M
authors.lastname: Fantasia
authors.forename: J
authors.initials: J
authors.lastname: Taft
authors.forename: M F
authors.initials: MF
authors.lastname: Beal
authors.forename: B
authors.initials: B
authors.lastname: Traynor
authors.forename: K
authors.initials: K
authors.lastname: Newhall
authors.forename: P
authors.initials: P
authors.lastname: Donofrio
authors.forename: J
authors.initials: J
authors.lastname: Caress
authors.forename: C
authors.initials: C
authors.lastname: Ashburn
authors.forename: B
authors.initials: B
authors.lastname: Freiberg
authors.forename: C
authors.initials: C
authors.lastname: O'Neill
authors.forename: C
authors.initials: C
authors.lastname: Paladenech
authors.forename: T
authors.initials: T
authors.lastname: Walker
authors.forename: A
authors.initials: A
authors.lastname: Pestronk
authors.forename: B
authors.initials: B
authors.lastname: Abrams
authors.forename: J
authors.initials: J
authors.lastname: Florence
authors.forename: R
authors.initials: R
authors.lastname: Renna
authors.forename: J
authors.initials: J
authors.lastname: Schierbecker
authors.forename: B
authors.initials: B
authors.lastname: Malkus
authors.forename: M
authors.initials: M
authors.lastname: Cudkowicz
mesh_terms: D000690:Amyotrophic Lateral Sclerosis / Q000188:drug therapy* / Q000378:metabolism / Q000503:physiopathology; D002490:Central Nervous System / Q000187:drug effects* / Q000378:metabolism / Q000503:physiopathology; D003067:Coenzymes; D004305:Dose-Response Relationship, Drug; D004361:Drug Tolerance / Q000502:physiology; D004734:Energy Metabolism / Q000187:drug effects / Q000502:physiology; D005260:Female; D016166:Free Radical Scavengers / Q000008:administration & dosage / Q000009:adverse effects; D006801:Humans; D008297:Male; D020714:Maximum Tolerated Dose; D008875:Middle Aged; D008928:Mitochondria / Q000187:drug effects / Q000378:metabolism; D009410:Nerve Degeneration / Q000188:drug therapy / Q000378:metabolism / Q000517:prevention & control*; D009474:Neurons / Q000187:drug effects* / Q000378:metabolism; D018696:Neuroprotective Agents / Q000008:administration & dosage* / Q000009:adverse effects / Q000097:blood; D014451:Ubiquinone / Q000008:administration & dosage / Q000009:adverse effects / Q000031:analogs & derivatives* / Q000097:blood
chemical_list: D003067:Coenzymes; D016166:Free Radical Scavengers; D018696:Neuroprotective Agents; D014451:Ubiquinone; C024989:coenzyme Q10